These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20440254)

  • 1. Diabetes and cardiovascular outcomes: finding the silver lining.
    Chen L; Shen YT; Shannon RP
    Minerva Cardioangiol; 2010 Apr; 58(2):253-67. PubMed ID: 20440254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of postprandial hyperglycemia in cardiovascular disease.
    Fava S
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):859-72. PubMed ID: 18570623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
    Milicevic Z; Raz I; Beattie SD; Campaigne BN; Sarwat S; Gromniak E; Kowalska I; Galic E; Tan M; Hanefeld M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
    Sjöholm A
    Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Ahmed I; Goldstein BJ
    Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of intensive glycemic control on cardiovascular disease: early reports from the ACCORD and ADVANCE Trials.
    Soo Yeon S; Nesto RW
    Rev Cardiovasc Med; 2008; 9(1):1-4. PubMed ID: 18418304
    [No Abstract]   [Full Text] [Related]  

  • 9. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes.
    Tushuizen ME; Diamant M; Heine RJ
    Postgrad Med J; 2005 Jan; 81(951):1-6. PubMed ID: 15640422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial glucose regulation and diabetic complications.
    Ceriello A; Hanefeld M; Leiter L; Monnier L; Moses A; Owens D; Tajima N; Tuomilehto J
    Arch Intern Med; 2004 Oct; 164(19):2090-5. PubMed ID: 15505121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and cardiovascular disease: explaining the relationship.
    Punthakee Z; Werstuck GH; Gerstein HC
    Rev Cardiovasc Med; 2007; 8(3):145-53. PubMed ID: 17938614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular manifestations of insulin resistance.
    Chahwala V; Arora R
    Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes.
    Colette C; Monnier L
    Horm Metab Res; 2007 Sep; 39(9):683-6. PubMed ID: 17846977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?
    Gerstein HC; Rosenstock J
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):137-54. PubMed ID: 15752926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P
    Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.
    Ceriello A; Davidson J; Hanefeld M; Leiter L; Monnier L; Owens D; Tajima N; Tuomilehto J;
    Nutr Metab Cardiovasc Dis; 2006 Oct; 16(7):453-6. PubMed ID: 16934443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention.
    Yamagishi S; Nakamura K; Takeuchi M; Imaizumi T
    Int J Clin Pharmacol Res; 2004; 24(4):129-34. PubMed ID: 15754918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetes and cardiovascular risk factors.
    Sharma MD; Farmer JA; Garber A
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():1-5. PubMed ID: 22106974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.